Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at
Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release [Yahoo! Finance]
Jupiter Endovascular Announces Completion of Enrollment in SPIRARE II Pivotal Trial [Yahoo! Finance]
Here's How Much a $1000 Investment in Vertex Pharmaceuticals Made 10 Years Ago Would Be Worth Today [Yahoo! Finance]
WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager [Yahoo! Finance]